Literature DB >> 10878727

Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations.

N S Lai1, J L Lan.   

Abstract

To evaluate the role of cerebrospinal fluid (CSF) anticardiolipin antibody (aCL) in lupus patients with neuropsychiatric manifestations, paired measurements of aCL, in the serum and CSF, were performed using the ELISA method in lupus patients (n=31) and controls with other medical diseases (n=8). High titers of CSF IgG-aCL were detected in cerebral lupus patients with lupus headache, acute psychosis, cognitive impairment, high cortical dysfunction, and altered consciousness. Intrathecal synthesis, rather than the diffusion of IgG-aCL from serum to compartment of the central nervous system, occurred in these NPLE patients. The binding of aCL to brain components might play a role in the development of neuropsychiatric manifestations in cerebral lupus patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878727     DOI: 10.1191/096120300678828415

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

Review 1.  Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment.

Authors:  Melanie J Harrison; Lisa D Ravdin
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

2.  Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease.

Authors:  Boris Sakic; David L Kirkham; David A Ballok; James Mwanjewe; Ian M Fearon; Joseph Macri; Guanhua Yu; Michelle M Sidor; Judah A Denburg; Henry Szechtman; Jonathan Lau; Alexander K Ball; Laurie C Doering
Journal:  J Neuroimmunol       Date:  2005-09-29       Impact factor: 3.478

Review 3.  Neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  David Hermosillo-Romo; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

4.  Neuropsychiatric lupus and association with cerebrospinal fluid immunoglobulins: a pilot study.

Authors:  Ljudmila Stojanovich; Dusica Smiljanich-Miljkovich; Roald Omdal; Boris Sakic
Journal:  Isr Med Assoc J       Date:  2009-06       Impact factor: 0.892

5.  Reversible dementia in systemic lupus erythematosus without antiphospholipid antibodies or cerebral infarction.

Authors:  S I Lee; H S Jeon; W H Yoo
Journal:  Rheumatol Int       Date:  2004-02-28       Impact factor: 2.631

Review 6.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

7.  Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus.

Authors:  Chaojun Hu; Wei Huang; Hua Chen; Guang Song; Ping Li; Qiang Shan; Xuan Zhang; Fengchun Zhang; Heng Zhu; Lin Wu; Yongzhe Li
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

Review 8.  Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

Authors:  Elias Manca
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-11       Impact factor: 10.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.